Immunotope   Report issue

For profit Phase 1
Founded: Doylestown PA United States (2002)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2007
NCT00437502
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

ocpm immunotherapeutic vaccine (1 trial)

ovarian cancer peptides (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Ovarian Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2